Related by context. All words. (Click for frequent words.) 71 Fabry Disease 70 Diabetic Nephropathy 68 Myelodysplastic Syndromes 68 Pulmonary Arterial Hypertension 68 Cutaneous T 68 Aviptadil 67 Chronic Lymphocytic Leukemia 67 Friedreich Ataxia 67 Severe Sepsis 67 Phase III Clinical Trial 66 Hepatocellular Carcinoma 66 Enzyme Replacement Therapy 66 Advanced Melanoma 66 Investigational Treatment 66 Myelofibrosis 66 Gout Drug 66 Drug Candidate 66 MPS VI 65 Chronic Myeloid Leukemia 65 Malignant Melanoma 65 Orphan Status 65 Renal Cell Carcinoma 65 Myelodysplastic Syndrome 65 Improved Survival 65 Liprotamase 65 Meets Primary Endpoint 65 Velaglucerase Alfa 65 Receives Orphan Drug Designation 65 Receives Positive Opinion 64 Phase III Trial 64 Bipolar Mania 64 Previously Treated 64 Diabetic Patients 64 Blood Pressure Drug 64 Chronic Heart Failure 64 Prolongs Survival 64 Clinical Trial Results 64 Romiplostim 64 Psoriasis Drug 64 Phase 2a Trial 64 Initiate Clinical Trial 64 Alemtuzumab 64 Gaucher disease 64 Chronic Hepatitis B 64 Overactive Bladder 64 Positive Opinion 64 FOLOTYN ® 64 Follicular Lymphoma 64 Files IND 64 Recombinant Human 64 EVIZON TM 64 Phase 2b Clinical Trial 64 Morquio 64 Acute Heart Failure 64 Allergic Rhinitis 63 Lambert Eaton Myasthenic 63 Receives Marketing Authorization 63 Safinamide 63 Metastatic Melanoma 63 Iron Overload 63 Hepatitis B Vaccine 63 NDA Submission 63 Soft Tissue Sarcoma 63 Phase 2b Trial 63 JAK2 Inhibitor 63 Plicera 63 Diabetic Neuropathic Pain 63 Azacitidine 63 Myeloma Patients 63 Atypical Hemolytic Uremic Syndrome 63 Lupus Nephritis 63 Clofarabine 63 Breast Cancer Recurrence 63 Cognitive Deficits 63 Age Related Macular 63 Idiopathic Pulmonary Fibrosis 63 Survival Benefit 63 FDA Accepts 63 Myelodysplastic Syndrome MDS 63 Icatibant 63 Benign Prostatic Hyperplasia 63 Dasatinib 63 Relapsed Refractory 63 Transdermal Patch 63 Juvenile Idiopathic Arthritis JIA 63 Civacir 63 Phase III Trials 63 Investigational Compound 63 Hereditary angioedema HAE 63 Decitabine 63 Autoimmune Disease 63 Investigational Drug 63 Personalized Immunotherapy 63 Rheumatoid Arthritis Patients 62 Chronic Sinusitis 62 Etanercept 62 Cetrorelix 62 Acute Myeloid Leukemia 62 Diabetic Macular Edema 62 Pivotal Phase III 62 Rheumatoid Arthritis Drug 62 HCV Protease Inhibitor 62 Initiate Phase 62 Rotavirus Vaccine 62 Interferon Beta 62 Granted Orphan Drug 62 Advanced Renal Cell 62 Novel Antibiotic 62 Asthma COPD 62 Phase IIb Trial 62 Chronic Myelogenous Leukemia 62 Hemophilia B 62 Bazedoxifene 62 Resistant Hypertension 62 Metastatic Colorectal Cancer 62 Raptiva R 62 Metabolic Disorder 62 Efficacious 62 Prostate Cancer Vaccine 62 Genzyme Cerezyme 62 Fast Track Status 62 Neovascular Age Related Macular 62 Well Tolerated 62 Therapeutic Vaccine 62 Major Depressive Disorder 62 Omalizumab 62 Hormone Refractory Prostate Cancer 62 Liver Cancer 62 Complicated Skin 62 Pirfenidone 62 Receptor Agonist 62 Multiple Myeloma Patients 62 Ambrisentan 62 Stomach Cancer 62 Lung Cancer Drug 62 Randomized Phase 62 taliglucerase alfa 62 Acute Myeloid Leukemia AML 62 Epilepsy Drug 62 Hepatitis C Virus 62 Gastric Cancer 62 Familial Adenomatous Polyposis FAP 62 Diamyd r 62 Orphan Designation 62 Slows Progression 62 Friedreich Ataxia FRDA 62 Improves Survival 62 Hematological Malignancies 62 Zavesca 62 Pivotal Phase 62 Silodosin 62 Inhaled Insulin 62 JAK Inhibitor 61 Beta Blocker 61 diarrhea predominant irritable 61 Subgroup Analysis 61 Nexavar sorafenib 61 Ceflatonin R 61 Tetrabenazine 61 FDA Orphan Drug 61 Antitumor Activity 61 Monoclonal Antibodies 61 Schizophrenia Drug 61 Dupuytren Contracture 61 Teva Provides Update 61 Successfully Completes Phase 61 Pulmonary Hypertension 61 Bladder Cancer 61 Treat Anemia 61 Novel Oral 61 Immune Mediated 61 Pompe Disease 61 Phase IIb Clinical Trial 61 GATTEX TM 61 Ustekinumab 61 Egrifta 61 Bortezomib 61 Oral Formulation 61 Atopic Dermatitis 61 Bosutinib 61 Sapacitabine 61 Vandetanib 61 Initiates Phase III 61 Present Preclinical Data 61 Stem Cell Treatment 61 Patients Treated With 61 Disease Progression 61 Intravenous Formulation 61 Improve Survival 61 Diabetic Neuropathy 61 Fabry disease 61 Immunotherapeutic 61 Therapeutic Potential 61 Elagolix 61 Ramelteon 61 Anticancer Agent 61 Dapagliflozin 61 Romidepsin 61 relapsed leukemia 61 terlipressin 61 Glatiramer Acetate 61 Gene Linked 61 Monoclonal Antibody 61 Pegloticase 61 Orphan Drug Status 61 Nilotinib 61 Advanced Prostate Cancer 61 Rituximab 61 ARIXTRA R 61 Pulmonary Arterial Hypertension PAH 61 SPRYCEL ® 61 Insulin Resistance 61 Bevacizumab 61 RNAi Therapeutics 61 Myeloid 61 FDA Okays 61 Patient Enrollment 61 Autoimmune Diseases 61 refractory chronic lymphocytic 61 Inflammatory Bowel Disease 61 Syndrome LEMS 61 Initiates Dosing 61 Renal Function 61 Treatment Resistant 61 Bronchiectasis 61 Slow Progression 61 Evoltra TM 61 Acute Attacks 61 Mipomersen 61 ATryn ® GTC recombinant 60 Submits NDA 60 Irinotecan 60 Investigational Agent 60 Leber Hereditary Optic Neuropathy 60 Completes Patient Enrollment 60 B Cell Lymphoma 60 Tesamorelin 60 Aztreonam Lysine 60 Novel Mechanism 60 Systemic Lupus Erythematosus SLE 60 Tyrosine Kinase Inhibitor 60 Ranolazine 60 Chronic Insomnia 60 Adjuvant Treatment 60 Severe Asthma 60 Newly Diagnosed 60 Tezampanel 60 Aryplase 60 Mylan Receives Approval 60 Cell Transplant 60 Arthritis Drug 60 REPLAGAL 60 Anticancer Drug 60 Bendamustine 60 Initiates Clinical 60 Initiates Clinical Trial 60 Bucindolol 60 pulmonary hypertension PH 60 Personalised Medicine 60 Systemic Delivery 60 SYCREST 60 Hepatitis B Virus 60 Diabetic Ulcers 60 Zarnestra 60 Initiates Phase II 60 complement inhibitor eculizumab 60 Lymphoid 60 Single Dose 60 Degarelix 60 ACE Inhibitors 60 atypical Hemolytic Uremic Syndrome 60 Ozarelix 60 Serious Infections 60 C1 Inhibitor 60 Naive Patients 60 Rheumatoid Arthritis RA 60 Eculizumab 60 Migraine Drug 60 Presents Positive 60 Renal Cancer 60 Febuxostat 60 Chronic Lymphocytic Leukemia CLL 60 Combination Therapy 60 Drug Shows Promise 60 Myelodysplastic Syndromes MDS 60 Castration Resistant Prostate Cancer 60 Aztreonam 60 Pivotal Trial 60 Rheumatoid Arthritis 60 Prospective Randomized 60 Pooled Analysis 60 Mouse Model 60 Receives Orphan Drug 60 Chronic lymphocytic leukemia 60 Drug Fails 60 Chronic Myeloid Leukemia CML 60 Cysteamine 60 acute porphyria 60 Vitrasert R 60 Seasonal Influenza Vaccine 60 Hypercholesterolemia 60 Drug Resistant 60 Signaling Pathway 60 Dendritic Cells 60 Fungal Infections 60 Improves Outcomes 60 Mantle Cell Lymphoma 60 Enlarged Prostate 60 Genetic Mutation 60 SUTENT ® 60 Torisel temsirolimus 60 orphan designation 60 Juvenile Idiopathic Arthritis 60 Hypertriglyceridemia 60 Oral Fingolimod 60 Maribavir 60 pancreatic enzyme replacement 60 Premenopausal Women 60 NICE Recommends 60 efalizumab 60 Oral Mucositis 60 Palonosetron 60 Phase 2b Study 60 Genetic Variant 60 Hepatocellular Carcinoma HCC 60 Cytarabine 60 Thyrogen 60 Secondary Hyperparathyroidism 60 HuMax TAC 60 kidney urologic 60 RNAi Therapeutic 60 Sjogren Syndrome 60 Tacrolimus 60 Oral Insulin 60 Cardiovascular Mortality 60 Artificial Pancreas 60 Successfully Treated 60 Janus kinase 60 Phase 1b Clinical Trial 60 Solid Tumors 60 Expanded Indication 60 Growth Hormone Deficiency 60 Diabetic Foot Ulcer 60 Therapeutic Antibodies 60 Antibody Discovery 60 homozygous FH 60 subependymal giant cell 60 proliferator activated receptor 60 Adjunctive Therapy 60 Combination REOLYSIN R 60 Treating Chronic 60 primary immunodeficiency 60 Advanced Colorectal Cancer 60 chronic eosinophilic leukemia 60 Bleeding Disorder 60 phenylketonuria 60 Non Hodgkin 60 Progressive Multifocal Leukoencephalopathy 60 Emerging Therapies 60 Severe Primary IGFD 60 HER2 Positive Breast Cancer 60 Alexion Pharma 60 Microalbuminuria 60 Amigal 60 CTAP# Capsules 60 Lupus Drug 60 pralatrexate injection folate analogue 60 Inflammatory Markers 60 Maroteaux Lamy syndrome 60 Genetic Disorders 60 Cerezyme imiglucerase 60 Receive Milestone Payment 60 Receives Fast Track 60 Granulocyte Colony Stimulating Factor 60 Hsp# Inhibitor 59 Initiates Enrollment 59 systemic juvenile idiopathic 59 Intracerebral Hemorrhage 59 Shows Efficacy 59 Shows Promise Against 59 Colorectal Cancer Patients 59 Phase 2a Clinical Trial 59 SHPT 59 Liver Failure 59 Begins Dosing 59 Omacetaxine 59 Elderly Patients 59 Levoleucovorin 59 rasagiline tablets 59 Sycrest 59 Prostate Cancer Patients 59 pharmacological chaperone 59 Randomized Phase II 59 Treatment Naive Patients 59 Node Positive 59 Desvenlafaxine 59 IND Application 59 Patient Enrolment 59 Disease Modifying 59 TB Vaccine 59 Systemic Lupus Erythematosus 59 Milestone Payment 59 Gene Mutation 59 Long Term Efficacy 59 Lenalidomide 59 Ovarian Cancer Patients 59 Immunosuppressant 59 Thelin tm 59 YONDELIS 59 Rilonacept 59 Glucocorticoid 59 systemic fungal infections 59 Cell Lymphoma 59 Pralatrexate 59 Gene Therapy Trial 59 gastrin analogue TT 59 Critical Limb Ischemia 59 Receives Approvable Letter 59 Cognitive Impairment 59 Eltrombopag 59 Carboplatin Paclitaxel 59 Amrubicin 59 Lung Cancer Trial 59 Rotavirus Vaccines 59 Stakeholder Opinions 59 Infected Patients 59 nephropathic cystinosis 59 Combo Therapy 59 Diamyd ® 59 Leukemias 59 autosomal recessive disorder 59 Aggressive Prostate Cancer 59 Kidney Stones 59 Temsirolimus 59 IL# PE#QQR 59 Osteoporosis Drug 59 Phase III Pivotal 59 Xyrem ® 59 Newly Diagnosed Multiple Myeloma 59 velaglucerase alfa 59 Muraglitazar 59 hypophosphatasia 59 Cell Transplants 59 Vidaza azacitidine 59 Calcium Acetate 59 Partial Onset Seizures 59 Mucositis 59 myelofibrosis polycythemia vera 59 Acute Ischemic Stroke 59 Acute Renal Failure 59 Novel Therapeutic 59 Combination Treatment 59 orphan medicinal product 59 progressive neurodegenerative disorder 59 Pancreatic Cancer 59 Kuvan R 59 chronic granulomatous disease 59 Genetic Testing 59 Increlex R 59 Pemphigus Vulgaris 59 Relapsing Remitting Multiple Sclerosis 59 Recombinant Protein 59 Tolvaptan 59 Sevelamer 59 Annamycin 59 Quark Biotech Inc. 59 Dose Ranging Study 59 HuMax CD4 59 Onalta 59 hypereosinophilic syndrome 59 Chronic Hepatitis C 59 Breast Cancer Treatment 59 Ovarian Cancer Treatment 59 Phenoptin 59 Trobalt 59 Metabolic Disorders 59 Acute Myelogenous Leukemia 59 Glufosfamide 59 chronic immune thrombocytopenic 59 Chronic Kidney 59 Generic Versions 59 Galantamine 59 Acute Leukemia 59 rheumatoid arthritis Crohn disease 59 Idera Pharmaceuticals 59 Cytotoxicity 59 granted Orphan Designation 59 Sipuleucel T 59 acetonide FA 59 Azathioprine 59 methylnaltrexone bromide 59 Pre Eclampsia 59 Anemia Drug 59 Previously Untreated 59 Saxagliptin 59 Erectile Dysfunction Drug 59 Pneumococcal Vaccine 59 Myozyme alglucosidase alfa 59 Mirapexin 59 Cell Proliferation 59 Smooth Muscle 59 Therapy Evaluation 59 Aripiprazole 59 Pramlintide 59 LUCASSIN 59 Tumor Necrosis Factor 59 PEGylated anti 59 Immunosuppression 59 Neuropathic Pain 59 idiopathic pulmonary fibrosis IPF 59 Esbriet pirfenidone 59 IV Busulfex 59 Earns Milestone Payment 59 Gene Variant 59 Inflammatory Arthritis 59 Cancer Vaccine 59 Ulcerative Colitis 59 Allogeneic 59 Quark Pharmaceuticals 59 Humanized Anti 59 Aptamer 59 Commercialize Novel 59 Epratuzumab 59 Iluvien ® 59 Cancer Vaccines 59 Relapsed Multiple Myeloma 59 AFREZZA TM 59 Genes Linked 59 Initiates Clinical Trials 59 FDA Approves Drug 59 TNF Tumor Necrosis Factor 59 Inflammatory Diseases 59 Stanate R 59 AA amyloidosis 59 Generalized Anxiety Disorder 59 II Clinical Trial 59 Mouse Models 59 Replacement Therapy 59 Archexin 59 Pivotal Study 59 Cholesterol Lowering Drug 59 Influenza Vaccine 59 Epidermal Growth Factor Receptor 59 Belimumab 59 Hyperkalemia 59 prGCD 59 Tumor Growth 59 Cholesterol Drug 59 Reovirus 59 MMR Vaccine 59 Pancreate 59 See CLINICAL PHARMACOLOGY 59 dual endothelin receptor antagonist 59 Announces Poster Presentations 59 Nexavar ® 59 Amgen Nplate 58 Receives Milestone Payment 58 gastrointestinal stromal tumors 58 diabetic nephropathy 58 Medidur ™ FA 58 Ocrelizumab 58 Submits Response 58 Ofatumumab 58 Files Investigational 58 TRO# 58 Nicotine Vaccine 58 Genetic Variation 58 Adjuvant Chemotherapy 58 Panic Disorder 58 Ganciclovir 58 glucokinase activator 58 Respiratory Virus 58 Renal Anemia 58 Initiates Phase 58 oropharyngeal candidiasis 58 Resubmission 58 Nucleoside 58 exocrine pancreatic insufficiency 58 Chronic Renal Failure 58 AAT Deficiency 58 Prediabetes 58 Patients Suffering 58 SNT MC# 58 Anti Tumor 58 Thrombin 58 R lenalidomide 58 PKU genetic 58 Exelixis XL# 58 Glioma 58 targeted radiotherapeutic 58 tiapamil 58 Pemetrexed 58 Respiratory Distress 58 Kineret ® 58 Hemorrhagic Stroke 58 Anticancer Compound 58 Oral Cladribine 58 Portal Hypertension 58 HepaGam B TM 58 Acute Decompensated Heart Failure 58 Acute Myelogenous Leukemia AML 58 Hospital Acquired Pneumonia 58 Cancer Treatments 58 Orally Active 58 Yondelis ® 58 AA Amyloidosis 58 BENLYSTA ® 58 Acute Pancreatitis 58 ALN TTR 58 Carcinoid tumors 58 PrandiMet 58 Aflibercept 58 Adjuvant Therapy 58 Corlux 58 Metastases 58 Campath ® 58 FDA Approvals 58 Clevudine 58 Chronic Constipation 58 Ebola Vaccine 58 Natalizumab 58 Dyslipidemia 58 Angiox ® 58 Cancidas 58 diabetes mellitus T2DM 58 familial hypercholesterolemia 58 Nocturia 58 Prostate Cancer Treatment 58 sodium glucose cotransporter 58 commercialize taliglucerase alfa 58 Voreloxin 58 YONDELIS R 58 tetrabenazine 58 CEQ# 58 Stronger Warnings 58 herpetic keratitis 58 Actemra tocilizumab 58 HoFH 58 Mycophenolate Mofetil 58 Tasigna nilotinib 58 Pancreatic 58 ELAPRASE 58 adult chronic ITP 58 Metastatic Prostate Cancer 58 Tasimelteon 58 Anticoagulant 58 Bipolar Depression 58 Vitro Diagnostic 58 Brain Tumors 58 Antisense 58 Short Stature 58 Cancer Immunotherapy 58 Functional Dyspepsia 58 Daclizumab 58 Kinase Inhibitors 58 Psoriatic Arthritis 58 Hypertensive Patients 58 neurogenic orthostatic hypotension 58 Ceflatonin 58 Tyrosine Kinase Inhibitors 58 antibody MAb 58 PNP inhibitor 58 von Willebrand disease 58 5 HT6 receptor 58 Preclinical Data 58 Ischemic Stroke 58 Tocilizumab 58 Kamada AAT 58 pancreatic insufficiency 58 Orphan Medicinal Product 58 Confirmatory Phase 58 Hyperlipidemia 58 cell lymphoma CTCL 58 Autoimmune 58 ZACTIMA TM ZD# 58 Cinryze ™ 58 Adalimumab 58 Is Well Tolerated 58 Lubiprostone 58 Ferumoxytol 58 Restless Legs Syndrome 58 Presents Preclinical Data 58 Malaria Vaccine 58 Malignant Glioma 58 HDAC Inhibitor 58 sorafenib tablets 58 Cachexia 58 First Patient Enrolled 58 Wet AMD 58 refractory acute promyelocytic 58 Naglazyme 58 Statistically Significant 58 Atomoxetine 58 Treating Heart Failure 58 Cethromycin 58 Uterine Fibroid Embolization 58 mastocytosis 58 Evoltra ® 58 Interferon beta 1a 58 Drug Combo 58 Gastrointestinal Liner 58 chronic myeloid 58 Hematopoietic 58 Soliris eculizumab 58 Hematopoietic Stem Cell Transplantation 58 phenylketonuria PKU 58 Paroxysmal Nocturnal Hemoglobinuria PNH 58 FDA Approvable Letter 58 lucinactant 58 Nuron Biotech 58 omacetaxine mepesuccinate 58 Antithrombin 58 Postmenopausal Women 58 Postmenopausal Osteoporosis 58 Randomized Study 58 Dacogen injection 58 Phase III Clinical Trials 58 Zenpep 58 Neoadjuvant Chemotherapy 58 autologous cellular immunotherapy 58 Solid Malignancies 58 Thyroid Cancer 58 Vaprisol 58 ORENCIA R 58 Blood Cancers 58 beta 1a 58 CNS Disorders 58 Cushing Syndrome 58 Drug Prevents 58 Islet Transplantation 58 Cardiovascular Outcomes 58 Orphan Drugs 58 Kidney Failure 58 Prophylactic Treatment 58 Demonstrates Positive 58 non alcoholic steatohepatitis 58 Hypoparathyroidism 58 developing Bicifadine serotonin 58 Hepatotoxicity 58 Psychiatric Disorders 58 Testosterone MDTS ® 58 Diabetic Retinopathy 58 Stem Cell Transplant 58 Vaccine Adjuvant 58 Myoblast 58 Neuroprotection 58 Sustained Reduction 58 Non Inferiority 58 Reminyl galantamine 58 Vicriviroc 58 E1 INT TM 58 Serdolect ® 58 Inhaled Corticosteroids 58 Carcinoid 58 HER2 Positive 58 Artery Disease 58 Neural Stem Cells 58 genetic lysosomal storage 58 Rexahn Pharmaceuticals 58 Fingolimod 58 STELARA TM 58 Psoriasis Patients 58 Technosphere ® 58 Blood Thinner 58 Hodgkin lymphoma HL 58 Inhalation Aerosol 58 Novel Therapies 58 SJIA 58 Pafuramidine 58 Simulect 58 Alnylam Pharma 58 Smallpox Vaccine 58 Glucagon 58 Fondaparinux 58 familial amyloidotic polyneuropathy FAP 58 Telavancin 58 Atypical Antipsychotics 58 Weight Loss Drug 58 hyperphenylalaninemia HPA due 58 Reflux Disease 58 Marketing Authorization 58 IND Filing 58 Rheumatoid 58 Sorafenib 58 VitiGam 58 Restless Legs Syndrome RLS 58 Treatment Shows Promise 58 Qutenza TM 58 mesylate 58 Pluristem Therapeutics 58 SNT-MC#/idebenone 58 Vimpat R 58 Hyperphosphatemia 57 Delayed Graft Function 57 Campath alemtuzumab 57 Hedgehog Pathway Inhibitor 57 Thyroid Hormone 57 Dalbavancin 57 severe oral mucositis 57 Inhalation Solution 57 Syncria R 57 Noxafil 57 Cannabinoid 57 dasatinib Sprycel ® 57 Efficacy Results 57 cutaneous T 57 Trodusquemine MSI 57 VAPRISOL 57 Congenital Emphysema 57 Cystinosis 57 Gestational Diabetes 57 Efficacy Trial 57 Protein Involved 57 HepaLife TM 57 Satraplatin 57 Donepezil 57 Microplasmin 57 Removab 57 Pamidronate 57 Study Evaluating 57 Preclinical Models 57 Cimzia ® certolizumab pegol 57 Multiple Ascending Dose 57 Chronic HCV 57 Avanafil 57 Duchenne muscular dystrophy DMD 57 Alogliptin 57 Circ Pharma 57 ThermoDox R 57 Velcade bortezomib 57 vWD 57 ERYtech Pharma 57 Taliglucerase alfa 57 Brentuximab Vedotin SGN 57 Cellcept 57 Potent Antiviral Activity 57 Anthracycline 57 Vernakalant 57 tuberous sclerosis TS 57 GTC recombinant form 57 Progenitor Cells 57 Fanconi Anemia 57 hematological malignancy 57 ST Elevation Myocardial 57 Glioblastoma Multiforme 57 STRIDE PD 57 Firazyr 57 Arranon 57 Thiazolidinediones 57 delta gamma agonist 57 cytomegalovirus infection 57 NAGS deficiency 57 Generalized Anxiety Disorder GAD 57 Ecallantide 57 Systemic Sclerosis 57 Swedish Orphan Biovitrum 57 Loxapine 57 Aurora Kinase 57 Nitazoxanide 57 VIVITROL ® 57 Autologous Stem Cell Transplantation 57 TRANSDUR ™ 57 Advanced Ovarian Cancer 57 Renal Failure 57 Amphotericin B 57 Vaccine Candidate 57 Brain Metastases 57 Pemphigus 57 Maven Semantic 57 Glucophage XR 57 Experimental Vaccine 57 Metastatic Renal Cell Carcinoma 57 Early Diagnosis 57 oxypurinol 57 Androgen Deprivation Therapy 57 Gleevec resistant 57 Presents Preclinical 57 Cervical Cancer Vaccine 57 Biomarker Study 57 Lennox Gastaut Syndrome 57 Bone Metastases 57 Dacogen decitabine 57 Subtypes 57 Preotact R 57 Stem Cell Transplants 57 therapeutic monoclonal antibodies 57 1 diabetes T1D 57 Vion Pharmaceuticals 57 Polycystic Ovary Syndrome 57 Molecular Diagnostic Test 57 Everolimus 57 StaphVAX R 57 Acute Exacerbations 57 Pazopanib 57 Reduced Risk 57 relapsed multiple myeloma 57 Roflumilast 57 Anti Tumor Activity 57 Sodium Injection 57 Diabetes Mellitus 57 Topical Treatment 57 secondary hyperparathyroidism 57 Lupus nephritis 57 Patients Receiving 57 Endometrial Cancer 57 Mutation Analysis 57 Clinical Trial Evaluating 57 Milnacipran 57 telomerase therapeutic 57 Bayer Onyx 57 Respiratory Syncytial Virus 57 Cardiotoxicity 57 Glycosylation 57 Gamunex C 57 Lung Cancer Patients 57 Denufosol 57 Lung Cancer Survival 57 Tumor Targeting 57 Relapsing Multiple Sclerosis 57 Ovarian Cancers 57 Peripheral Artery Disease 57 Sprycel dasatinib 57 Valproic Acid 57 relapsing remitting MS RRMS 57 TBC# 57 gastrointestinal stromal tumors GIST 57 Mg Uk 57 Squamous Cell Carcinoma 57 Shows Promising 57 Small Molecule 57 Valsartan 57 Antipsychotic 57 Desmoteplase 57 rilonacept 57 Peginterferon alfa 2b 57 generation purine nucleoside 57 HuMax EGFr 57 SGLT2 57 Treatment Naïve 57 Malignant Mesothelioma 57 Ridaforolimus 57 MELAS 57 Rescula 57 ATTR PN 57 Sudhir Agrawal D.Phil 57 Factor Receptor 57 Unresectable 57 Avastin bevacizumab 57 Cancer Patients Treated 57 Marketing Authorisation Application 57 Ondansetron Injection USP 57 hoFH 57 UPLYSO 57 Phase IIa Clinical Trial 57 Respiratory Syncytial Virus RSV 57 Radiofrequency Ablation RFA 57 Attenuates 57 NASH Huntington 57 Gastrointestinal Disorders 57 lixivaptan 57 Low Dose 57 Apaziquone 57 metastatic malignant 57 Demonstrated Significant 57 immune thrombocytopenic purpura 57 Cellegesic 57 Rotigotine 57 Kinase Inhibitor 57 Phospholipase A2 57 Gene Variation 57 Neovascular 57 Commence Phase 57 Anticancer Activity 57 XAGRID 57 Grants Orphan Drug 57 Metabolic Disease 57 VPRIV 57 von Willebrand Disease 57 ZARS Pharma 57 RNA Interference 57 Evoltra 57 acyclovir Lauriad R 57 Venous Thromboembolism 57 Minimally Invasive Treatment 57 GW# [003] 57 arthritis PsA 57 First Patient Dosed 57 Receives Complete Response 57 Ischemic 57 GA GCB 57 mycosis fungoides 57 VIVUS Qnexa 57 Epoetin Alfa 57 Certican 57 neuropathic pain metabolic diseases 57 Boceprevir 57 Chronic Inflammatory 57 Autoimmune Disorders 57 Appears Safe